Given the “glioblastoma IDH-wild-type” is defined by what it is lacking (i.e., lack of IDH1 and IDH2 hotspot mutations) rather than what it is harboring, many opportunities exist to identify new CNS tumor entities with unique genetic and epigenetic features within this HGG group. The gene discussed is IDH2; the disease is central nervous system neoplasm.